logo

KILITCH vs ZIMLAB: Stock Comparison

KILITCH DRUGS INDIA vs ZIM LABORATORIESUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

ZIM LABORATORIES is the larger company by market capitalisation. KILITCH DRUGS INDIA shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KILITCH leads 9; ZIMLAB leads 1 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KILITCHZIMLAB

Valuation lens

What price are you paying?

Market CapContext only
₹668 Cr
₹720 Cr
P/E RatioKILITCH has the lower reading
26.1x ✓
182.5x
P/B RatioZIMLAB has the lower reading
2.81x
2.51x ✓
EPSKILITCH has the higher reading
₹0.83 ✓
₹-0.75
Book ValueContext only
₹79.19
₹55.31
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
ZIMLAB is the larger company
₹720 Cr vs ₹668 Cr
P/E Ratio
KILITCH has a lower P/E
26.1x vs 182.5x
P/B Ratio
ZIMLAB has a lower P/B
2.51x vs 2.81x
EPS
KILITCH has higher earnings per share
₹0.83 vs ₹-0.75
Revenue Growth (TTM YoY)
KILITCH has faster revenue growth
46.3% vs -3.36%
EPS Growth (TTM YoY)
KILITCH has faster EPS growth
26.5% vs -47.01%
ROE
KILITCH has a higher ROE
9.73% vs 1.97%
ROCE
KILITCH has a higher ROCE
7.73% vs 3.86%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKILITCHZIMLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKILITCHZIMLAB
Live Price₹202.11₹132.12
Day Change-0.82%-0.13%
Volume68,20673,408
52-Week High₹439₹159.81
52-Week Low₹117.25₹59.31
Distance from 52W High-53.96%-17.33%

Valuation

MetricKILITCHZIMLAB
Market Cap₹668 Cr₹720 Cr
P/E Ratio26.1x182.5x
P/B Ratio2.81x2.51x
EPS₹0.83₹-0.75
Book Value₹79.19₹55.31
Dividend Yield0%0%

Growth

MetricKILITCHZIMLAB
Revenue Growth (TTM YoY)46.3%-3.36%
EPS Growth (TTM YoY)26.5%-47.01%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricKILITCHZIMLAB
ROE9.73%1.97%
ROCE7.73%3.86%
Net Margin12.81%1.56%
Operating Margin23.33%5.72%
Debt to Equity0.27x0.42x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricKILITCHZIMLAB
Promoter Holding63.77%30.3%▼ 0.06 pp
FII Holding0.11%▼ 0.01 pp0.17%▲ 0.14 pp
DII Holding0.5%▲ 0.5 pp1.19%▼ 0.14 pp
Public Holding35.62%▼ 0.49 pp68.34%▲ 0.06 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KILITCH DRUGS INDIA and ZIM LABORATORIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.